- Home
- ELAN vs LEGN Comparison
ELAN vs LEGN Comparison
Compare ELAN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAN
- LEGN
- Stock Information
- Founded
- ELAN 1954
- LEGN 2014
- Country
- ELAN United States
- LEGN United States
- Employees
- ELAN N/A
- LEGN N/A
- Industry
- ELAN Biotechnology: Pharmaceutical Preparations
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ELAN Health Care
- LEGN Health Care
- Exchange
- ELAN Nasdaq
- LEGN Nasdaq
- Market Cap
- ELAN 6.6B
- LEGN 5.4B
- IPO Year
- ELAN 2018
- LEGN 2020
- Fundamental
- Price
- ELAN $14.29
- LEGN $35.49
- Analyst Decision
- ELAN Buy
- LEGN Strong Buy
- Analyst Count
- ELAN 7
- LEGN 12
- Target Price
- ELAN $15.17
- LEGN $77.09
- AVG Volume (30 Days)
- ELAN 5.3M
- LEGN 2.1M
- Earning Date
- ELAN 08-07-2025
- LEGN 08-08-2025
- Dividend Yield
- ELAN N/A
- LEGN N/A
- EPS Growth
- ELAN N/A
- LEGN N/A
- EPS
- ELAN 0.75
- LEGN N/A
- Revenue
- ELAN $4,427,000,000.00
- LEGN $728,303,000.00
- Revenue This Year
- ELAN $4.28
- LEGN $65.49
- Revenue Next Year
- ELAN $4.67
- LEGN $53.76
- P/E Ratio
- ELAN $19.07
- LEGN N/A
- Revenue Growth
- ELAN 1.42
- LEGN 112.46
- 52 Week Low
- ELAN $8.02
- LEGN $27.34
- 52 Week High
- ELAN $15.78
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- ELAN 66.32
- LEGN 58.50
- Support Level
- ELAN $13.16
- LEGN $32.42
- Resistance Level
- ELAN $14.15
- LEGN $35.07
- Average True Range (ATR)
- ELAN 0.39
- LEGN 1.69
- MACD
- ELAN -0.05
- LEGN -0.09
- Stochastic Oscillator
- ELAN 83.70
- LEGN 44.24
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.